This was a single-center, open-label, 2-period, fixed-sequence Phase 1 trial in 16 healthy adult male and female subjects (at least 7 subjects per sex). In the first period, subjects received treatment 1 (T1; single dose of 100 mg PTV on Day 1). In the second period, subjects received 40 mg qd ESO from Day -3 to Day 1 followed by a single dose of 100 mg PTV on Day 1. The wash-out period between PTV administrations in T1 and T2 was at least 4 weeks.
To investigate the effect of esomeprazole (ESO) on the pharmacokinetics of pritelivir (PTV), and to investigate the safety and tolerability of PTV.